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Abstract 
Purpose 
To assess and compare the diagnostic performance of magnitude-reconstruction 
chemical-shift-encoded magnetic resonance imaging (MRI-M) and complex-reconstruction 
chemical-shift-encoded magnetic resonance imaging (MRI-C) for diagnosis of hepatic steatosis 
in subjects with severe obesity without known non-alcoholic fatty liver disease (NAFLD), using 
contemporaneous histology as reference. 
Materials and Methods 
This is an IRB-approved, HIPAA-compliant, two-center, cross-sectional study of a larger 
prospective trial that recruited patients without known NAFLD consecutively between October 
2010 and March 2015 to undergo research MRI exams 1-2 days prior to clinical-care weight-loss 
surgery. Proton density fat fraction (PDFF) was estimated using MRI-M and MRI-C. Liver 
biopsies were obtained intraoperatively. Using histologically-determined presence of steatosis as 
the reference standard, receiver operating characteristics (ROC) analyses were used to identify 
MRI-M- and MRI-C-derived PDFF thresholds for diagnosing steatosis. Bootstrapped-based tests 
were used to compare their diagnostic performance.  
Results 
A total of 81 patients (67 female, 14 male, average age 48.2) were recruited for this 
study. MRI-M and MRI-C had areas under the ROC curve of 0.951 and 0.947, respectively, for 
diagnosing hepatic steatosis. For MRI-M, the Youden-index-based PDFF threshold of 6.5% 
provided 0.87 sensitivity (95% confidence internal: 0.75, 0.95), 0.96 specificity (0.81, 0.99), and 
0.90 total accuracy (0.82, 0.96). For MRI-C, a PDFF threshold of 6.8%, provided 0.90 sensitivity 
(0.77, 0.96), 0.96 specificity (0.81, 0.99), and 0.91 total accuracy (0.83, 0.97). Differences in 
performance parameters between MRI-M and MRI-C were not statistically significant.  
Conclusion 
MRI-M- and MRI-C-derived PDFF is accurate for non-invasive diagnosis of hepatic 
steatosis in subjects with severe obesity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Confounder-corrected chemical-shift-encoded magnetic resonance imaging (CSE-MRI) 
methods have been developed to estimate the proton density fat fraction (PDFF), an emerging 
quantitative biomarker of liver fat content defined as the ratio of fat proton density to total (fat 
and water) proton density (1-4). These methods minimize or correct for biases caused by T1, 
T2*, and the spectral complexity of fat. MRI-C also addresses noise-related bias and the effects 
of eddy currents (5-10). Studies have shown that PDFF correlates well with histologically-
determined hepatic steatosis grades and suggest that it can diagnose the presence of steatosis, 
using contemporaneous histology as reference (11, 12-17). 
A recently published MRI-M-based PDFF threshold of 6.4% had 86% sensitivity and 
83% specificity to diagnose the presence of hepatic steatosis (17). However, that study enrolled 
subjects with known or clinically-suspected nonalcoholic fatty liver disease (NAFLD), resulting 
in the cohort being enriched in NAFLD. Since only 7% of enrolled subjects lacked steatosis, the 
specificity estimate had wide 95% confidence intervals (CIs) (0.36, 1.00). This may have also 
altered the actual specificity estimate and optimal diagnostic threshold. Additionally, the study 
did not include MRI-C. Since MRI-M is known to underestimate PDFF compared to MRI-C, a 
cutoff developed for MRI-M may be suboptimal for MRI-C (18), and their relative accuracy for 
diagnosing hepatic steatosis remains uncertain. 
Therefore, the purpose of this study was to assess and compare the diagnostic 
performance of MRI-M- and MRI-C-derived PDFF for detecting hepatic steatosis in subjects 
with severe obesity, using contemporaneous histology as reference. These subjects are at risk for 
but not known a priori to have hepatic steatosis and so are expected to have a more balanced 
distribution of hepatic steatosis, which may permit more robust estimation of diagnostic 
thresholds and their performance.  
Materials and Methods  
Study Design and Subjects 
This Health Insurance Portability and Accountability Act (HIPAA)-compliant, two-
center, cross-sectional study of a wider prospective study was approved by our institutional 
review board (IRB). Inclusion criteria included adults with severe obesity (BMI≥35kg/m2, 
age≥18 years) undergoing weight loss surgery (laparoscopic sleeve gastrectomy or laparoscopic 
Roux-en-Y gastric bypass). Exclusion criteria included contraindications to MRI (e.g., 
claustrophobia, metallic implants), excessive alcohol consumption (>1.5 drinks per day), and 
type 1 diabetes. 
Subjects provided written informed consent and underwent MR examinations at multiple 
time points as part of a wider longitudinal study examining changes in PDFF following weight 
loss surgery (WLS). PDFF estimates for this study were derived from MR examinations that 
took place after a two-to-four week, very low-calorie liquid diet and immediately prior to WLS. 
Subjects were excluded from this cross-sectional study if one or both of the MRI sequences 
methods was not acquired, or if intraoperative biopsy was not obtained. Subject demographics, 
time intervals from MRI to surgery, and reasons for exclusion were recorded.  
Liver biopsy and histology 
Surgeons performed wedge and/or core biopsies during WLS based on their judgment of 
the safest procedure in individual subjects. Wedge biopsies, typically about 1-4 cm2 at the 
surface and 1-2 cm of depth, were taken from the anterior surface of the left lateral sector of the 
liver. Core biopsies, each weighing approximately 20-30 mg, were taken from the superficial 
portions of the same sector to avoid blood vessels and major bile ducts. Histology slides were 
prepared with hematoxylin and eosin, Masson’s trichome, and iron stains.       
Blinded to the MRI results, two hepatopathologists (each with at least three years of 
experience) independently scored each biopsy specimen (wedge, core, or both) in each subject. 
Together they reviewed each specimen, adjudicated any disagreements, and assigned a final 
consensus score for each of several histology features. 
Based on the estimated percentage of hepatocytes containing microscopically visible fat 
vacuoles, hepatic steatosis was scored in a granular fashion as 0%, 1%, 5%, 10%, 15%, 20%…, 
100%. Whenever both core and wedge biopsies were performed, the scores were averaged to 
yield composite scores, which were then converted into the 4-point ordinal scoring system 
described by the NASH CRN (19): grade 0, <5%; grade 1, 5-33%, grade 2, 34-66%; grade 3, 
>66%). The hepatic steatosis score for each subject was further binarized as steatosis present 
(grade ≥ 1) or absent (grade 0). Lobular inflammation was scored according to the number of 
inflammatory foci per magnification field 200X as follows: grade 0, no inflammation; grade 1, 
less than 2 foci; grade 2, 2–4 foci; and grade 3, more than 4 foci. Portal inflammation was scored 
as follows: grade 0, none; grade 1, mild; grade 2, moderate; or grade 3, marked. Fibrosis was 
scored as follows: stage 0, none; stage 1, perisinusoidal or periportal; stage 2, perisinusoidal and 
portal or periportal; stage 3, bridging fibrosis; or stage 4, cirrhosis. Hepatocellular iron was 
scored on an ordinal scale from 0 to 4. The NAFLD Activity Score (NAS), defined as the 
unweighted sum of the scores for steatosis (0-3), lobular inﬂammation (0-3), and ballooning (0-
2), was represented in Table 2 as scores of ≤ 3 (low possibility of steatohepatitis), 3.5 – 4.5, and 
≥ 5 (high possibility of steatohepatitis) (19). Similar to the process for steatosis, individual scores 
for other histologic features were averaged for subjects with both types of biopsy, which 
occasionally resulted in half-scores. 
Subject preparation and positioning 
Subjects were instructed to fast for at least four hours prior to MR examination. At one 
center, subjects underwent non-contrast MR examinations on a 3.0T GE twin-speed with an 8-
element torso phased-array coil scanner (GE Signa, EXCITE HDxt, GE Healthcare, Waukesha, 
WI). At the other center, subjects underwent non-contrast MR examinations on a 3.0T GE 750 
scanner with a 32-element torso phased-array coil; if the subject did not fit, a 1.5T 450W GE 
wide bore scanner with an 8-element torso phased-array coil was used instead. Coils were 
centered over the liver. At once center, dielectric pads were placed over the abdomen for 3.0T 
examinations to reduce B1 heterogeneity. Each MR examination lasted about 60 minutes.  
MR sequences  
A 2D spoiled gradient-recalled echo (SPGR) sequence was used for MRI-M while a 3D 
SPGR sequence was used for MRI-C. Axial images covering as much of the liver as possible 
within one breath hold were acquired with the parameters listed in Table 1. These parameters are 
similar to those used in prior MRI-M and MRI-C studies (5-10, 16-17). For both methods, PDFF 
maps were generated in-line on the scanner computer from the corresponding source data. 
Source images, PDFF maps, and fat and water images (for MRI-C) were transferred for off-line 
analysis. 
MR analysis 
Using the Osirix imaging software (Pixmeo, Geneva, Switzerland) and blinded to 
histologic results, trained image analysts (1-3 years experience) placed regions of interest (ROIs) 
on the fifth echo of the source images (MRI-M) or water images (MRI-C). ROIs were placed on 
anatomic images rather PDFF maps to avoid feedback bias. These particular images were 
selected beforehand because they consistently provide adequate visualization of hepatic anatomy 
to guide proper ROI placement. For each sequence, one ROI was placed in each of the nine 
Couinaud liver segments, making sure to include only liver parenchyma and to exclude vessels, 
bile ducts, lesions, and artifacts. In some subjects, one or more of the nine planned ROIs could 
not be placed on one or both sequences, usually because the segment was not included in the 
scanned volume and sometimes due to artifacts. ROIs were then propagated to PDFF maps and 
averaged to obtain the mean PDFF values. 
Statistical analysis 
Statistical analyses were performed by a staff biostatistician under the supervision of a 
faculty statistician, both with more than 20 years of experience, using R software package 
version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria). Cohort anthropometric, 
laboratory, and histologic measures were summarized. MRI-M and MRI-C PDFF averages were 
computed for each subject using only the segmental PDFFs available for both sequences. Thus, 
in case of a missing segmental PDFF for either sequence, unpaired segments were excluded, and 
partial averages based only on paired segments were computed for both sequences. 
Receiver operating characteristic curve (ROC) analysis was performed for each MR 
sequence using histologically-determined presence of steatosis (grade ≥ 1) as the reference 
standard. Areas under the ROCs (AUC) and their significances were calculated to assess 
diagnostic accuracy.           
The diagnostic threshold for each sequence was selected from the PDFF estimates based 
on the Youden index, which provided the highest specificity and sensitivity combination. 
Performance parameters (sensitivity, specificity, total accuracy, negative predictive value, and 
positive predictive value) and their confidence intervals were calculated for each threshold. 
Bootstrap-based tests were used to compare their performance. Bonferroni's correction for 
multiple comparisons was applied.  Only p-values < 0.0125 would be considered significant to 
ensure a family-wise significance level of 0.05.  
To examine the possible confounding impact of demographic and other liver histologic 
features (listed in Table 2) on diagnostic accuracy, a Bayesian Information Criterion (BIC)-based 
stepwise logistic regression was used.  
Results  
Subjects 
The total number of recruited subjects who satisfied the inclusion criteria was 81. A 
summary of cohort characteristics at the time of MRI is presented in Table 2. Of the 81, ten 
subjects lost weight between enrollment and MRI; hence, BMIs measured at the MRI visit 
ranged below the inclusion requirement of ≥ 35 kg/m2. Two thirds of subjects had steatosis, 
mainly grade 1, while the remaining third had no steatosis. Forty-four had both core and wedge 
biopsies, twenty-eight had only wedge biopsies, and nine had only core biopsies. Among the 44 
subjects with both biopsies, they were concordant in 29 subjects for the presence of steatosis (≥ 
5% fat-containing hepatocytes); they were concordant in 14 subjects for the absence of steatosis 
(<5% fat-containing hepatocytes). In the one subject with discordant scores, the wedge biopsy 
had 5% steatotic hepatocytes (grade 1) and the core biopsy had 1% steatotic hepatocytes (grade 
0). Since the average of the two percentages (3%) was <5%, the final assigned steatosis grade 
was 0 and the outcome was binarized as steatosis absent. Relatively small proportions of subjects 
had advanced histologic features on at least one biopsy specimen as defined by bridging fibrosis 
or cirrhosis: 6/81 (7%); lobular inflammation grade ≥ 2: 7/81 (9%); portal inflammation grade ≥ 
2: 3/81 (4%); iron grade ≥ 2: 11/81 (8%), or any ballooning 16/81 (20%).  
PDFF Data 
PDFF was estimated at 3.0T in 77 (95%) of the 81 subjects, and at 1.5T in the remaining 
four (5%). Over the entire cohort, PDFF values ranged from 1.0% to 32.5% for MRI-M and 
1.4% to 31.5% for MRI-C. PDFF values were slightly but consistently lower for MRI-M than 
MRI-C, 9.3% ± 6.8 vs 9.9% ± 6.7. The mean difference of 0.6% was statistically significant (p-
value < 0.0001). Figure 1 shows representative MRI-PDFF maps at 3.0T of subjects with and 
without hepatic steatosis.  
ROC Analysis 
Figure 2 shows ROC curves for the diagnosis of hepatic steatosis. MRI-M and MRI-C 
had AUCs of 0.951 (p < 0.0001) and 0.947 (p < 0.0001), respectively. This difference was not 
statistically significant (bootstrap-based p-value = 0.70).   
Youden-index PDFF Threshold Diagnostic Performance and Comparison 
Table 3 summarizes performance metrics of the Youden-index-based thresholds for both 
sequences. The Youden-index-based PDFF threshold for MRI-M was 6.5%, which provided 0.87 
sensitivity (95% CI: 0.75 – 0.95), 0.96 specificity (0.81 – 1.00), and 0.90 total accuracy (0.82 – 
0.96). Seven subjects had false negative results; one had a false positive result. The Youden-
index-based PDFF threshold for MRI-C was 6.8%, which provided 0.90 sensitivity (95% CI: 
0.77 – 0.96), 0.96 specificity (0.81 – 1.00), and 0.91 total accuracy (0.83 – 0.97). Six subjects 
had false negative results; one had a false positive result. For the one subject with discordant 
results between wedge and core biopsies, the PDFF estimated by each MRI method was 5.9%; 
therefore, each method was classified as true negative for this subject.  
Differences between sequences were not significant for sensitivity, specificity, or total 
accuracy, with bootstrap-based p-values of 0.855, 0.460, and 0.840, respectively (Table 4). 
A BIC-based, regression-model search for confounders to classification accuracy 
revealed BMI to be the sole significant predictor of classification errors.  Higher BMI was 
associated with lower odds of misclassification error (odds ratio = 0.8, chi-square p-value = 
0.037). No histological measures had a significant confounding effect on the relationship 
between PDFF and steatosis grade. 
Discussion 
This study showed that both MRI-M and MRI-C are highly accurate for the diagnosis of 
hepatic steatosis in subjects with severe obesity. With one exception, core and wedge biopsies 
were concordant in all subjects in which both biopsies were obtained. The Youden-index, 
diagnostic PDFF thresholds for MRI-M and MRI-C were very similar and their diagnostic 
performance parameters were not significantly different. 
Our PDFF thresholds for diagnosis of hepatic steatosis are within the range of those 
reported previously for each MR sequence (12-14, 16-17). Tang et al (17) reported that an MRI-
M-based PDFF threshold of 6.4% had 0.86 sensitivity and 0.83 specificity to diagnose steatosis 
while an earlier study (16) reported an MRI-M-based PDFF diagnostic threshold of 6.4% with 
0.97 sensitivity and 1.00 specificity. Kühn et al (11) found that an MRI-C-determined PDFF 
threshold of 5.1% had 0.86 sensitivity and 1.00 specificity to differentiate between no versus any 
steatosis. Importantly, the Tang and Kuhn thresholds were derived from different cohorts than 
ours. Tang’s cohort comprised of subjects with known or clinically-suspected NAFLD, with 
hepatic steatosis absent in only 7% of subjects. Kuhn’s cohort comprised of subjects with clinical 
indications for liver biopsy. Conversely, our study consisted of adults with severe obesity 
undergoing WLS without known hepatic steatosis a priori. This higher proportion and absolute 
number of subjects without hepatic steatosis permitted more precise specificity estimation: the 
CIs for the specificity estimates in this study (0.81 – 0.99 for both sequences) are narrower than 
those reported by Tang et al (0.36 – 1.00) and Kuhn et al (0.48 – 1.00) (16-17). 
A separate study reported that a lower PDFF threshold (~3%) is associated with the 
presence of metabolic syndrome in obese adolescent girls (20). The lower threshold associated 
with metabolic syndrome raises the possibility that small quantities of liver fat, currently 
considered within the normal range by conventional histological grading systems, may in fact be 
pathologic. Further research is needed to confirm the lower PDFF threshold associated with 
metabolic syndrome and to understand the biological relevance. 
Our results suggest that MRI-M- and MRI-C-derived PDFFs have comparable diagnostic 
accuracy. As reported previously, we observed a slight PDFF underestimation by MRI-M 
relative to MRI-C (18). MRI-M-derived PDFFs in this study were consistently and significantly 
lower than MRI-C PDFF with a mean difference of 0.64% (p-value < 0.0001). However, an 
underestimation of < 1% point is not expected to be clinically meaningful. Another difference is 
that the range of measurable PDFF is up to 50% for MRI-M but up to 100% for MRI-C. This 
difference is of minor relevance in the liver, since hepatic PDFF rarely exceeds 50% (15-17). In 
our cohort, the maximum PDFF was 32.5% as measured by MRI-M and 31.5% as measured by 
MRI-C. Therefore, either method is likely to be suitable for assessing hepatic steatosis in the 
large majority of subjects.  
Using multivariable analysis, we examined the impact of several demographic, 
anthropometric, and histologic variables on classification errors. Our analysis found that only 
BMI was a significant predictor of misclassification (p = 0.0377) with lower BMI associated 
with more frequent classification errors. This is an unexpected finding, since we would have 
anticipated that larger habitus, not smaller, might have reduced accuracy by lessening image 
quality and/or promoting imaging artifacts. Further research is needed to confirm and elucidate 
the mechanism for this finding. Unlike Schwimmer et al (21) and Idilman et al (15), we did not 
find that hepatic fibrosis or any other histology feature confounded the performance of MRI for 
assessing hepatic steatosis, but the failure to detect a confounding effect may have reflected the 
relatively mild degree of fibrosis and other histological abnormalities in our population.  
One limitation of our study is that it was performed at two academic centers with 
expertise in PDFF quantification using both MRI methods. Additionally, a single scanner 
manufacturer was utilized at both sites. At one of the centers, subjects who were too large for the 
3.0T scanner had to undergo MR examination using a larger 1.5T scanner. Although studies have 
suggested excellent reproducibility of PDFF estimation across different field strengths, scanners, 
and reconstruction methods (22-27), agreement is not perfect, and it is conceivable that the 
cutoffs identified in our study may require modification in different settings, such as community 
centers with less expertise or different equipment available.  
Since we enrolled only adults, the applicability of our study’s PDFF thresholds to the 
pediatric population at risk for NAFLD needs to be verified. The pathophysiology and histology 
of adult versus pediatric NAFLD are not the same and still not fully understood (28-29).  
Because safety was paramount, we obtained biopsies based on the surgeon’s judgment 
rather than obtaining the same type of biopsy in all subjects. Additionally, as done in prior 
studies (11, 15-17), PDFF values in this study were averaged from PDFF measurements obtained 
from each of the nine liver segments to better reflect the liver’s total fat content and reduce 
sampling variability. Conversely, biopsies sampled only the left lateral sector, potentially 
introducing sampling variability (30-31). We also could not co-localize ROIs with the exact 
biopsy location, since the latter could not be recorded reliably intraoperatively. Given that PDFF 
and histology assess for steatosis using widely disparate volumes, it should be expected that they 
do not correlate perfectly, and this may account in part for the misclassifications in our study. 
Furthermore, MRI estimates the tissue proton density fat fraction on a continuous scale while 
histology estimates the proportion of hepatocytes containing microscopically resolvable 
triglyceride droplets on an ordinal scale.  
In summary, this study further supports the use of MRI-M- and MRI-C-derived PDFF as 
an accurate, quantitative, non-invasive alternative to histopathologic analysis for the diagnosis of 
hepatic steatosis in subjects with severe obesity at risk of developing NAFLD. Future studies are 
needed to confirm our results in scanners of other manufacturers, in different study populations 
including children, and in community centers. 
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Table 1: Key acquisition parameters for magnitude-reconstruction chemical-shift-encoded 
magnetic resonance imaging (MRI-M) and complex-reconstruction chemical-shift-encoded 
magnetic resonance imaging (MRI-C) at 3.0T and 1.5T. TE = echo time; TR = repetition time. 
 
 
 
 
 
 
 
 
 
 
 Field 
strength 
TE (ms) TR (ms) Flip 
angle (°) 
Bandwidth 
(kHz)  
Slice 
thickness 
(mm) 
Matrix Number 
of slices  
Length 
of single 
breath 
hold 
(sec) 
MRI-M 3.0T 1.15, 2.3, 
3.45, 4.6, 
5.75, 6.9 
120-170 10 ±125 8 192-256 
X 160-
256 
8-20 12-34 
1.5T 2.3, 4.6, 
6.9, 9.2, 
11.5, 
13.8 
170 10 ±83 8 192-256 
X 160-
256 
8-20 12-34 
MRI-C 3.0T 1.2, 2.2, 
3.2, 4.2, 
5.2, 6.2 
8.6 3 ±125 8 256 X 
128 
32 20 
1.5T 1.2, 3.2, 
5.2, 7.2, 
9.2, 11.2 
13.4 5 ±125 8 256 x 
160 
32 20 
Table 2: Cohort (n=81) demographic and liver histology characteristics. 
Characteristic Value 
Sex  
     Female 67 (82.7%) 
     Male 14 (17.3%) 
Race  
     Black 2 (2.5%) 
     Other 8 (9.9%) 
     White 71 (87.7%) 
Ethnicity  
     Hispanic/Latino 12 (14.8%) 
     Non-Hispanic/Latino 69 (85.2%) 
Age (years) 48.2 ± 12.5 (23.7 – 70.6)* 
Mean body mass index (kg/m2) 41.7 ± 5.5 (32.5 – 56.8)* 
Waist-to-Hip Ratio  0.89 ± 0.10 (0.74 – 1.19)* 
Steatosis grade**  
     0; <5% hepatocytes 27 (33.3%) 
     1; 5%-33% hepatocytes 39 (48.1%) 
     2; 33%-66% hepatocytes 11 (13.6%) 
     3; >66% hepatocytes 4 (4.9%) 
Lobular inflammation***  
     0; no foci 48 (59.3%) 
     0.5 7 (8.6%) 
     1; <2 foci per 200x field 19 (23.5%) 
     1.5 3 (3.7%) 
     2; 2-4 foci per 200x field 4 (4.9%) 
     3; >4 foci per 200x field 0 (0%) 
Portal Inflammation***  
     0; none 47 (58%) 
     0.5  13 (16%) 
     1; mild 18 (22.2%) 
     1.5 3 (3.7%) 
     2; moderate 0 (0%) 
     3; marked 0 (0%) 
Hepatocellular ballooning***  
     0; none 65 (80.2%) 
     0.5 1 (1.2%) 
     1; few balloon cells  10 (12.3%) 
     1.5 1 (1.2%) 
     2; many cells/prominent ballooning 4 (4.9%) 
Iron grade***  
     0 44 (54%) 
     0.5 8 (10%) 
     1 13 (16%) 
     1.5 4 (5%) 
     2 5 (6%) 
     3 2 (3%) 
      N/A† 5 (6%) 
Fibrosis stage***  
     0; no fibrosis 33 (41.2%) 
     0.5 7 (8.8%) 
     1; perisinusoidal or periportal 22 (27.5%) 
     1.5 10 (12.5%) 
     2; perisinusoidal and periporal  2 (2.5%) 
     2.5 1 (1.2%) 
     3; bridging fibrosis 4 (5.0%) 
     4; cirrhosis 1 (1.2%) 
      NA† 1 (1.2%) 
NAS***‡  
      ≤ 3  68 (84%) 
      3.5 – 4.5 9 (11%) 
      ≥ 5 4 (5%) 
Mean MR-determined PDFF value (%)  
     MRI-M 9.3 ± 6.8 (1.0 —32.5)* 
     MRI-C 9.9 ± 6.7 (1.4—31.5)* 
Note— *Data are averages ± standard deviations, with ranges in parentheses.  
**A 4-point ordinal steatosis score was derived from the granular steatosis score or, for subjects 
with both wedge and core biopsies, from the average granular steatosis score.  
***Half grades/stages are due to averaging results from wedge and core biopsies. 
† No data available for these subjects. 
‡ NAS stands for the NAFLD Activity Score, which is the unweighted sum of the scores for 
steatosis (0-3), lobular inﬂammation (0-3), and ballooning (0-2). Scores of ≤ 3 (low possibility of 
steatohepatitis), 3.5 – 4.5 (moderate possibility of steatohepatitis), and ≥ 5 (high possibility of 
steatohepatitis). 
 
 
 
 
Table 3: Summary of performance metrics of the magnitude-based magnetic resonance imaging 
(MRI-M-) and complex-based magnetic resonance imaging (MRI-C-) derived, Youden-index-
based proton density fat fraction (PDFF) thresholds for diagnosing hepatic steatosis in subjects 
with severe obesity undergoing weight-loss surgery, using histology as reference. 
Sequence Youden-
index-based 
PDFF 
threshold (%) 
Sensitivity Specificity PPV NPV Total 
accuracy 
MRI-M 6.5 0.87 (47/54) 
[0.75 – 
0.95] 
0.96 (26/27) 
[0.81 – 
1.00] 
0.98 
(47/48) 
[0.89 – 
1.00] 
0.79 
(26/33) 
[0.61 – 
0.91] 
0.90 
(73/81) 
[0.82 – 
0.96] 
MRI-C 6.8 0.89 (48/54) 
[0.77 – 
0.96] 
0.96 (26/27) 
[0.81 – 
1.00] 
0.98 
(48/49) 
[0.89 – 
1.00] 
0.81 
(26/32) 
[0.64 – 
0.93] 
0.91 
(74/81) 
[0.83 – 
0.97] 
Note—numerators and denominators of percentages are in parentheses. Numbers in brackets are 
95% confidence intervals. PPV = positive predictive value; NPV = negative predictive value. 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Difference between performance metrics of magnitude-based magnetic resonance 
imaging (MRI-M-) and complex-based magnetic resonance imaging (MRI-C-) derived proton 
density fat fraction (PDFF) thresholds and their statistical significance (95% confidence interval 
and p-values).  
Performance 
Parameter 
Estimate  
(MRI-M – 
MRI-C) 
95% CI lower 
limit 
95% CI upper 
limit 
Bootstrap-based 
p-value 
AUC 0.004 -0.014 0.021 0.700 
Sensitivity -0.02 -0.06 0.10 0.855 
Specificity 0.00 -0.12 0.00 0.460 
Total accuracy -0.01 -0.04 0.05 0.840 
Note: Each estimate was calculated by subtracting MRI-C value from MRI-M value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1: Magnetic resonance imaging (MRI) proton density fat fraction (PDFF) maps generated 
by magnitude-based magnetic resonance imaging (MRI-M, top row) and complex-based 
magnetic resonance imaging (MRI-C, bottom row) for subjects without (left column: 55-year old 
woman, body mass index 33.2 kg/m2) versus with (right column: 58-year old woman, body mass 
index 44.7 kg/m2) hepatic steatosis. Notice that MRI-M estimates PDFF from 0-50% whereas 
MRI-C estimates PDFF from 0 to 100%, as reflected in the scale bars. As a result, adipose tissue 
appears dark on MRI-M maps but bright on MRI-C maps. Despite these differences, close PDFF 
agreement is observed in the liver.  
 Figure 2: Overlaid magnitude-based magnetic resonance imaging (MRI-M) and complex-based 
magnetic resonance imaging (MRI-C) receiver operating characteristic (ROC) curves with their 
respective area under the ROC curve (AUC) and p-values for diagnosing hepatic steatosis. 
 
